Thrombogenicity of Lipoprotein A: Laboratory Study Defining the Prothrombotic Effects of Lipoprotein A

Cardiac Disease Clinical Trial

Official title:

Thrombogenicity of Lipoprotein A: a Prospective, Non - Randomised, Open Label, Proof of Concept, Laboratory Study Defining the Prothrombotic Effects of Lipoprotein A

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05330819
• Other study ID #: 297224
• Status: Not yet recruiting
• Start date: May 1, 2022
• Est. completion date: September 2022

Study information

• Verified date: April 2022
• Source: South Tees Hospitals NHS Foundation Trust
• Contact: Doctor
• Phone: 01325 381100
• Email: pyotr.telyuk[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Brief summary: Lipoprotein a (Lp(a)) is an independent risk factor for cardiovascular and cerebrovascular disease. Traditionally, the pathogenic role of Lp(a) has been linked to the atherogenic process given its similarity to low density lipoprotein (LDL), however there is a potential for prothrombotic tendencies given its resemblance to plasminogen. The emerging evidence suggests that the prothrombotic properties of Lp(a) contribute not only to arterial but also to venous thrombosis. Lp(a) has the potential to participate in thrombogenesis via several mechanisms: probable platelet aggregation and activation, increased expression of plasminogen activator inhibitor - 1, and reduced production of plasmin. Prior data suggests that Lp(a), can also modify fibrin clot permeability and its susceptibility to lysis. These observations have potentially important implications in patients with a history of myocardial infarction, stroke and venous thromboembolic disease. The investigators propose to conduct a proof-of-concept study to assess the prothrombotic effects of Lp(a), using both quantitative and qualitative assessment of thrombosis, in particular analysing clot structure and dynamics.

Description:

Thrombogenicity of Lp(a) study is a two-centre, open-label, non-randomised, observational laboratory study defining the prothrombotic effects of Lp(a). The study is aimed to answer the question of effect of LP(a) on thrombus formation in patients with previous history of myocardial infarction. Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using the following techniques: i) Badimon chamber: this will assess thrombogenicity of flowing blood. Approximately 50 mls of blood drawn from the antecubital vein, will be passed through the chamber at 37 degrees C. The chamber will contain strips of porcine aorta denuded of its intima layer to promote thrombosis. The resulting thrombus will be fixed in formalin, stained with haematoxylin/eosin and the amount of thrombus quantified using the Image ProPlus software. ii) Scanning electron microscope (SEM): A sample of the resulting thrombus from the above experiment will be gold stained and the thrombus ultrastructure analysed under SEM. This will allow for examination and analysis of the microstructure morphology and characterization of the thrombus. iii) Thromboelastography (TEG) is a comprehensive assay of the overall clotting process, a method used to provide a global assessment of whole blood, coagulation and clot lysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: September 2022
• Est. primary completion date: August 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients with stable coronary artery disease and previous history of myocardial infarction currently receiving aspirin monotherapy;
• Age = 18;
• Patients who can provide written informed consent for participation in the trial;

Exclusion Criteria:

• Haematological disorders (anaemia, malignancy, bleeding disorder)
• Malignancy (currently diagnosed or under investigation)
• Current smokers
• Chronic liver disease
• End stage renal disease (eGFR<30ml/min)
• Use of corticosteroids or non-steroidal anti-inflammatory agents
• Patients taking aspirin at dose of above 75mg daily
• Patients receiving anticoagulant treatment or antiplatelet treatment other than aspirin
• Unable to consent

Related Conditions & MeSH terms

• Cardiac Disease
• Cardiovascular Diseases
• Heart Diseases
• Lipid Metabolism Disorders

Intervention

Other:
• Non-interventional
Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.

Locations

Country	Name	City	State
United Kingdom	South Tees Hospitals NHS FT	Middlesbrough	Teesside

Sponsors (2)

Lead Sponsor	Collaborator
South Tees Hospitals NHS Foundation Trust	Newcastle-upon-Tyne Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LP(a) thrombogenicity	Quantity of thrombus measured following Badimon Perfusion Chamber Test	Through study completion, an average of 1 year